Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticleRxFiles

Improper administration

Silent culprit of drug therapy problems

Jessie Vitic, Erin Yakiwchuk and Alex Crawley
Canadian Family Physician February 2023, 69 (2) 107-112; DOI: https://doi.org/10.46747/cfp.6902107
Jessie Vitic
Pharmacist in Nokomis, Sask.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin Yakiwchuk
Assistant Professor in the College of Pharmacy and Nutrition at the University of Saskatchewan in Saskatoon.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Crawley
Associate Director of the RxFiles Academic Detailing Program at the University of Saskatchewan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alex.crawley@usask.ca
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • PDF
Loading

Proper timing of medication administration can maximize effectiveness, minimize adverse effects, optimize adherence, and prevent unnecessary polypharmacy. This is because drug-food interactions and medication temporal patterns can have substantial effects on patient outcomes. This article examines some commonly used medications that are prone to improper administration and outlines solutions for addressing these challenges. Consideration should also be given to clinical judgment, consistency, and individualization of drug therapy to patient and caregiver needs beyond the general recommendations found in this article.

Case presentation

Anna, a frail 81-year-old woman, is new to your practice after another family doctor in your area retired. Anna has multiple medical conditions including hypertension, nonvalvular atrial fibrillation (for about 1 year), diabetes, hypothyroidism, and osteoporosis. She was diagnosed with Alzheimer disease by your colleague approximately 1 year ago and began treatment for iron deficiency anemia 3 months ago. Anna also has a long list of medications (Table 1).

At Anna’s second appointment with you she is accompanied by her daughter Jane. Anna lives with Jane and relies on her for assistance with instrumental activities of daily living, as well as bathing and dressing. They would prefer that Anna continue living at home for as long as she can. Jane manages Anna’s medications by filling a dosette box for her and reminding her to take them, proudly stating that Anna “never misses a dose.” However, Jane has some concerns about Anna’s health: she is often tired during the day but wanders in the night, and she has pedal edema, which makes wearing shoes uncomfortable. Anna previously wore compression stockings but has been resistant to this lately because donning them is difficult.

During Anna’s last appointment (1 month ago), you decided not to make changes to her medications but sent her for bloodwork. You also requested that her pharmacy perform a full medication review, including details on the time of day that medications are given, administration with food, and any over-the-counter medications not on your file. Table 1 and Box 1 show her current medication regimen, bloodwork, and vital signs. As you review her medications, you identify several potential issues.

View this table:
  • View inline
  • View popup
Table 1.

Anna’s detailed medication history

Box 1.

Anna’s medical history

Recent bloodwork

Results

  • eGFR=69 mL/min

  • Serum creatinine=71 μmol/L

Levels within normal limits

  • TSH=0.87 mIU/L

  • T4=16 pmol/L

  • Electrolytes

  • Calcium

  • Lipid panel

Abnormal levels

  • Increased HbA1c=8.4% (3 mo ago=8.9%)

  • Decreased Hb=103 g/L

  • Decreased iron=5.4 μmol/L

  • Decreased TIBC=49 μmol/L

  • Decreased TSAT=11%

  • Decreased ferritin=13 μg/L

  • Decreased MCV=76.8 fL

Physical examination

Findings on presentation

  • Blood pressure=132/84 mm Hg

  • Heart rate=74 beats/min

  • No shortness of breath

  • 2+ pitting edema

  • MMSE=20/30 (vs 23 upon dementia diagnosis)

Previous chart history findings

  • Echocardiogram 2 y ago, LVEF=59%

  • Intolerance to sulfonylureas

eGFR—estimated glomerular filtration rate, Hb—hemoglobin, HbA1c—hemoglobin A1c, LVEF—left ventricular ejection fraction, MCV—mean corpuscular volume, MMSE—Mini-Mental State Examination, T4—thyroxine, TIBC—total iron bonding capacity, TSAT—transferrin saturation, TSH—thyroid-stimulating hormone.

Timing medications with food

Some medications have increased absorption and effectiveness when taken with food (eg, nitrofurantoin,1 metformin extended release [XR],2 and rivaroxaban doses ≥15 mg).3,4 Food can also be a useful tool for improving tolerability and reducing the gastrointestinal side effects of many drugs (including metformin, prednisone, iron supplements, and nonsteroidal anti-inflammatory drugs).5,6 However, some medications have substantially decreased absorption in the presence of food (eg, bisphosphonates,7 levothyroxine,8 iron supplements,9 and cloxacillin10), which reduces clinical effect. Table 2 describes the change in bio-availability (extent of absorption) among selected medications when taken with food compared with an empty stomach.7,11-32

View this table:
  • View inline
  • View popup
Table 2.

Bioavailability of common medications when taken with or without food

Anna is taking several medications that are time sensitive with regard to meals. Her metformin XR is both better absorbed (increases by 50%) and better tolerated if taken with food.17,18 Her dose of rivaroxaban is recommended by guidelines33 and product manufacturers3 to be taken with a meal to increase bioavailability (from 66% to 80% up to 100%) and thus avoid inadequate anticoagulation that may occur under fasting conditions (note that rivaroxaban doses of ≤10 mg have high absorption regardless of food intake).19-21 Her weekly alendronate should not be taken with breakfast since this decreases absorption by 85% to 90%, rendering it ineffective.7,11 Only bisphosphonates that are delayed release (DR) can be taken after food (eg, risedronate DR).34 Although Anna’s levothyroxine has reduced bioavailability when taken with food (decreased by about 15%),8,16,35 the dose can be titrated to target thyroid-stimulating hormone (TSH) and thyroxine (T4) levels. Thus, consistency with levothyroxine administration is most important. In this case, because Anna’s TSH and T4 levels are within normal limits, the timing of levothyroxine does not necessarily have to be changed.

In summary, it is important that Anna take her metformin XR–sitagliptin combination and rivaroxaban with sizable meals; her alendronate with a glass of water and without food or other medications; and her levothyroxine consistently either with or without food.

Important drug-mineral interactions

Chelating medications must be properly spaced from minerals. When polyvalent cations (calcium, magnesium, aluminum, or iron) are administered with certain drugs (such as ciprofloxacin or tetracycline), the formation of an insoluble “chelate” complex can prevent absorption.36,37 Table 3 lists some common chelating medications and how to time their administration (typically about 2 hours before or roughly 4 hours after minerals).7,35,38-44 Of note, many polyvalent cations are found in food (eg, calcium in milk) and in over-the-counter products (eg, multivitamins, antacids), which can inadvertently create drug interactions. Minerals can also negatively affect each other: for example, calcium can reduce iron absorption.25,45 Switching calcium supplements to dietary sources while decreasing product interactions may be preferred by guidelines (as long as dairy is not taken with chelating medications).46 Since chelation and intestinal interactions can drastically decrease bioavailability—sometimes by more than 90%—identification of these problems and subsequent separation is necessary to maximize effectiveness.47

View this table:
  • View inline
  • View popup
Table 3.

Chelating medications and cation administration times: Cations include calcium, magnesium, aluminum, and iron.

Anna has prescriptions for 2 chelating medications (levothyroxine and alendronate) and 1 polyvalent cation (calcium carbonate). Anna will not adequately absorb her alendronate if it is not spaced apart from her calcium supplement as well as dietary interactions. Her levothyroxine does not necessarily require separation if her thyroid test results remain stable.

Medications at the optimal time of day

Chronotherapeutics refers to timing medical treatment based on circadian rhythms to increase the effectiveness of medications or to minimize adverse effects.48,49 Evidence in this field of medicine is emerging but sometimes conflicting.

Dihydropyridine calcium channel blockers. These, such as amlodipine and nifedipine, can induce pedal edema. Strategies to minimize this side effect include lowering the dose, switching to a different drug, combining with an angiotensin-converting enzyme inhibitor,50 or administering at bedtime. A randomized study involving nifedipine XR showed edema rates of 13.4% when nifedipine was administered in the morning compared with 1% in the evening.51 Since leg elevation (eg, lying with a pillow under the legs) can reduce edema by shifting fluid back to the heart,52,53 timing peak drug levels at night may lessen daytime symptoms. Chronotherapeutic studies have yet to be conducted on other dihydropyridine calcium channel blockers in this context.

Stimulating medications. These medications, such as bupropion, methylphenidate, and steroids, are best taken in the morning to prevent sleep disturbances, while sedating medications (such as fluvoxamine, amitriptyline, and olanzapine) should be taken in the evening to avoid daytime drowsiness.54,55,56 Although originally recommended by the manufacturer to be taken in the evening,57 donepezil can be taken in the morning.58 A small trial of 54 patients taking donepezil showed that those who were randomized to take donepezil in the evening had worse sleep outcomes than those in the morning group.59

Antihypertensive medications. The timing of antihypertensive medications is contentious. Evidence from clinical trials showed absolute risk reductions in cardiovascular events of 11% and 5.4%, respectively, when antihypertensives were taken at bedtime compared with the morning.60,61 However, methodologic issues make this evidence uncertain.62 More recently, a 5-year study revealed no difference in risk of cardiovascular events between bedtime and morning administration (3.4% vs 3.7%, hazard ratio=0.95).63 Upcoming results of a Canadian trial will shed additional light on the subject.64 Prioritizing adherence by giving antihypertensives at the most convenient time of day for patients is likely best.

Statins. Statins are conventionally taken at bedtime since cholesterol synthesis peaks then, but this is not always required. Long-acting statins (atorvastatin, rosuvastatin, and fluvastatin XR) can be taken at any time of day without consequence. Short-acting statins (fluvastatin, lovastatin, pravastatin, and simvastatin) have half-lives of 6 hours or less and may be best taken at night for maximum low-density lipoprotein reduction.65,66 Of note, hard outcomes such as cardiovascular events and mortality have not yet been examined in relation to timing.

Anna’s donepezil can be stimulating and is best taken in the morning to minimize sleep disturbances. Her amlodipine could be trialed at bedtime to see if this reduces her leg swelling and increases the antihypertensive effect, although data to support this approach are limited. Evidence suggests Anna’s atorvastatin can be taken at any time of day (although if she were taking a short-acting agent such as simvastatin, bedtime administration might be best).

Case resolution

After analyzing Anna’s bloodwork, evaluating medication administration patterns, and consulting with Jane and Anna, you recommend the following:

  • Switch donepezil from evening to morning administration to attempt to improve Anna’s sleep.

  • Have Anna take her weekly alendronate as soon as she wakes up, with plain water, at least 30 minutes before breakfast and other medications to maximize absorption. Alternatively, a switch could be made to risedronate DR to allow for administration with a meal and other medications, but this formulation is not covered by government drug benefit plans in most Canadian provinces and may cost Anna about $15 more per month.

  • Move rivaroxaban administration from bedtime to suppertime (her largest meal) to maximize absorption and thus maximize stroke prevention.

  • Move Anna’s metformin XR and sitagliptin to suppertime (her largest meal) to maximize absorption.

  • Administer amlodipine at supper in the hope of improving her pedal edema. Alternatively, adding an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker might help.50

  • Move calcium carbonate to suppertime to avoid interactions with alendronate and levothyroxine. Alternatively, consideration may be given to stopping Anna’s calcium supplement and encouraging dietary calcium sources (which would still require spacing from alendronate and levothyroxine).

  • Continue levothyroxine at breakfast, since Anna’s thyroid function test results are within range. However, you reorder thyroid function tests for 6 weeks from now, since you suspect Anna’s levothyroxine dose may have to be adjusted after removal of the calcium drug interaction.

Since you are substantially changing Anna’s medication routine, you also recommend that her pharmacy place her medications in blister packs.

Conclusion

Hidden interactions—both helpful and harmful—can impact drug absorption, so it is important to properly space medications to avoid interference from chelates and to note when administration with or without food may be necessary. Similarly, taking medications at the wrong time of day can result in unwanted side effects or hinder therapeutic effect. When managing medical conditions that can be reactively dose adjusted based on laboratory results (eg, TSH and T4 levels, international normalized ratio, and cholesterol levels), consistency in medication administration is usually the top priority. However, optimal administration time is most essential when the effectiveness of medications, like bisphosphonates, cannot be readily monitored. By analyzing an existing medication regimen before adding new drugs, the harms associated with polypharmacy and prescribing cascades can be reduced.

In Anna’s case, her medication schedule changed to 3 times per day. This type of schedule may not be manageable for every patient. When caregiver support for “perfect” medication timing is limited, alternative medications may need to be chosen (or new therapeutic goals set). Providers can find the balance between optimal medication timing and a schedule that works for patients and caregivers.

Acknowledgment

We thank Loren Regier and Brent Jensen for review of the manuscript.

Footnotes

  • Competing interests

    The RxFiles Academic Detailing Program is funded through a grant from the Saskatchewan Health Authority to the University of Saskatchewan; additional “not for profit; not for loss” revenue is obtained from sales of books and online subscriptions. No financial assistance was obtained for this publication.

  • This article is eligible for Mainpro+ certified Self-Learning credits. To earn credits, go to https://www.cfp.ca and click on the Mainpro+ link.

  • La traduction en français de cet article se trouve à https://www.cfp.ca dans la table des matières du numéro de février 2023 à la page e38.

  • Copyright © 2023 the College of Family Physicians of Canada

References

  1. 1.↵
    1. Wijma RA,
    2. Huttner A,
    3. Koch BCP,
    4. Mouton JW,
    5. Muller AE.
    Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. J Antimicrob Chemother 2018;73(11):2916-26.
    OpenUrlCrossRef
  2. 2.↵
    1. Schwartz SL,
    2. Gordi T,
    3. Hou E,
    4. Cramer M,
    5. Heritier M,
    6. Cowles VE.
    Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. Expert Opin Drug Metab Toxicol 2008;4(9):1235-43.
    OpenUrlPubMed
  3. 3.↵
    1. Chang P.
    Important drug warning Xarelto (rivaroxaban) film-coated oral tablets. Distribute this information to your members [letter]. Titusville, NJ: Janssen Pharmaceutical Inc; 2013. Available from: http://www.abcardio.org/wp-content/uploads/2016/11/REMS.pdf. Accessed 2023 Jan 10.
  4. 4.↵
    1. Deng J,
    2. Zhu X,
    3. Chen Z,
    4. Fan CH,
    5. Kwan HS,
    6. Wong CH, et al.
    A review of food-drug interactions on oral drug absorption. Drugs 2017;77(17):1833-55.
    OpenUrl
  5. 5.↵
    1. Singh P,
    2. Yoon SS,
    3. Kuo B.
    Nausea: a review of pathophysiology and therapeutics. Therap Adv Gastroenterol 2016;9(1):98-112.
    OpenUrlCrossRef
  6. 6.↵
    1. Hughes C,
    2. Petrucha R.
    Nausea and vomiting. Ottawa, ON: Canadian Pharmacists Association; 2021. Available from: https://www.e-therapeutics.ca/.
  7. 7.↵
    1. Wiesner A,
    2. Szuta M,
    3. Galanty A,
    4. Paśko P.
    Optimal dosing regimen of osteoporosis drugs in relation to food intake as the key for the enhancement of the treatment effectiveness—a concise literature review. Foods 2021;10(4):720.
    OpenUrl
  8. 8.↵
    1. Colucci P,
    2. Yue CS,
    3. Ducharme M,
    4. Benvenga S.
    A review of the pharmacokinetics of levothyroxine for the treatment of hypothyroidism. Eur Endocrinol 2013;9(1):40-7. Epub 2013 Mar 15.
    OpenUrl
  9. 9.↵
    1. Stoffel NU,
    2. von Siebenthal HK,
    3. Moretti D,
    4. Zimmermann MB.
    Oral iron supplementation in iron-deficient women: how much and how often? Mol Aspects Med 2020;75:100865. Epub 2020 Jul 7.
    OpenUrl
  10. 10.↵
    1. Kislak JW,
    2. Eickhoff TC,
    3. Finland M.
    Cloxacillin: activity in vitro, and absorption and urinary excretion in normal young men. Am J Med Sci 1965;249:636-46.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Gertz BJ,
    2. Holland SD,
    3. Kline WF,
    4. Matuszewski BK,
    5. Freeman A,
    6. Quan H, et al.
    Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58(3):288-98.
    OpenUrlCrossRefPubMed
  12. 12.
    1. Ogura Y,
    2. Gonsho A,
    3. Cyong JC,
    4. Orimo H.
    Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption. J Bone Miner Metab 2004;22(2):120-6.
    OpenUrlPubMed
  13. 13.
    1. McClung MR,
    2. Miller PD,
    3. Brown JP,
    4. Zanchetta J,
    5. Bolognese MA,
    6. Benhamou CL, et al.
    Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. Osteoporos Int 2012;23(1):267-76. Epub 2011 Sep 27.
    OpenUrlPubMed
  14. 14.
    Actonel risedronate sodium (as the hemi-pentahydrate) tablets USP 5 mg, 30 mg, 35 mg, and 150 mg. Actonel DR risedronate sodium (as the hemi-pentahydrate) delayed-release tablets 35 mg [product monograph]. Markham, ON: Allergan Pharma Co; 2017. Available from: https://pdf.hres.ca/dpd_pm/00040591.PDF. Accessed 2023 Jan 11.
  15. 15.
    1. Fukase H,
    2. Tanaka S,
    3. Ohishi H,
    4. Oikawa I,
    5. Furuie H.
    Phase I clinical trial of NE-58095 DR, a risedronate delayed-release tablet: dose escalation and food effect. Jpn J Clin Pharmacol Ther 2018;49(3):113-24.
    OpenUrl
  16. 16.↵
    1. Wenzel KW,
    2. Kirschsieper HE.
    Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977;26(1):1-8.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Bristol-Myers Squibb Company
    . Glucophage (metformin hydrochloride) tablets. Glucophage XR (metformin hydrochloride) extended-release tablets [product label]. Silver Spring, MD: US Food and Drug Administration; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf. Accessed 2023 Jan 9.
  18. 18.↵
    Janumet sitagliptin (as sitagliptin phosphate monohydrate) and metformin hydrochloride tablets. Janumet XR sitagliptin (as sitagliptin phosphate monohydrate) and metformin hydrochloride modified-release tablets [product monograph]. Rahway, NJ: Merck Canada Inc; 2022. Available from: https://www.merck.ca/en/wp-content/uploads/sites/20/2021/04/JANUMET-CI_E.pdf. Accessed 2023 Jan 10.
  19. 19.↵
    1. Stampfuss J,
    2. Kubitza D,
    3. Becka M,
    4. Mueck W.
    The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 2013;51(7):549-61.
    OpenUrlCrossRefPubMed
  20. 20.
    Xarelto (rivaroxaban) [product monograph]. Titusville, NJ: Janssen Pharmaceuticals Inc; 2021. Available from: https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/XARELTO-pi.pdf. Accessed 2023 Jan 10.
  21. 21.↵
    1. Bratsos S.
    Pharmacokinetic properties of rivaroxaban in healthy human subjects. Cureus 2019;11(8):e5484.
    OpenUrl
  22. 22.
    1. Cancelo-Hidalgo MJ,
    2. Castelo-Branco C,
    3. Palacios S,
    4. Haya-Palazuelos J,
    5. Ciria-Recasens M,
    6. Manasanch J, et al.
    Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin 2013;29(4):291-303. Epub 2013 Feb 6.
    OpenUrlCrossRefPubMed
  23. 23.
    1. Lopez A,
    2. Cacoub P,
    3. Macdougall IC,
    4. Peyrin-Biroulet L.
    Iron deficiency anaemia. Lancet 2016;387(10021):907-16. Epub 2015 Aug 24.
    OpenUrlCrossRefPubMed
  24. 24.
    1. Hallberg L,
    2. Björn-Rasmussen E,
    3. Ekenved G,
    4. Garby L,
    5. Rossander L,
    6. Pleehachinda R, et al.
    Absorption from iron tablets given with different types of meals. Scand J Haematol 1978;21(3):215-24.
    OpenUrlPubMed
  25. 25.↵
    Iron preparations: oral (CPhA monograph). Ottawa, ON: Canadian Pharmacists Association; 2017. Available from: https://www.e-therapeutics.ca/. Accessed 2022 Apr 10.
  26. 26.
    1. Li N,
    2. Zhao G,
    3. Wu W,
    4. Zhang M,
    5. Liu W,
    6. Chen Q, et al.
    The efficacy and safety of vitamin C for iron supplementation in adult patients with iron deficiency anemia: a randomized clinical trial. JAMA Netw Open 2020;3(11):e2023644.
    OpenUrl
  27. 27.
    1. Lynch SR,
    2. Cook JD.
    Interaction of vitamin C and iron. Ann N Y Acad Sci 1980;355:32-44.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Stoffel NU,
    2. Cercamondi CI,
    3. Brittenham G,
    4. Zeder C,
    5. Geurts-Moespot AJ,
    6. Swinkels DW, et al.
    Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 2017;4(11):e524-33. Epub 2017 Oct 9.
    OpenUrlPubMed
  29. 29.
    1. Stoffel NU,
    2. Zeder C,
    3. Brittenham GM,
    4. Moretti D,
    5. Zimmermann MB.
    Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica 2020;105(5):1232-9. Epub 2019 Aug 14.
    OpenUrlAbstract/FREE Full Text
  30. 30.
    1. Lee H,
    2. Poon MC,
    3. Allan GM.
    Iron dosing frequency. Can Fam Physician 2021;67:436 (Eng), e142-3 (Fr).
    OpenUrlFREE Full Text
  31. 31.
    1. Bates TR,
    2. Sequeira JA,
    3. Tembo AV.
    Effect of food on nitrofurantoin absorption. Clin Pharmacol Ther 1974;16(1):63-8.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Sidell S,
    2. Bulger RJ,
    3. Brodie JL,
    4. Kirby WM.
    Cloxacillin, a new oral synthetic penicillin. Comparisons with oxacillin. Clin Pharmacol Ther 1964;5:26-34.
    OpenUrlPubMed
  33. 33.↵
    1. Andrade JG,
    2. Aguilar M,
    3. Atzema C,
    4. Bell A,
    5. Cairns JA,
    6. Cheung CC, et al.
    The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol 2020;36(12):1847-948. Epub 2020 Oct 22.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Kinov P,
    2. Boyanov M.
    Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation. Int J Womens Health 2012;4:167-74. Epub 2012 Apr 12.
    OpenUrlPubMed
  35. 35.↵
    1. Jonklaas J,
    2. Bianco AC,
    3. Bauer AJ,
    4. Burman KD,
    5. Cappola AR,
    6. Celi FS, et al.
    Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid 2014;24(12):1670-751.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Carpenter M,
    2. Berry H,
    3. Pelletier AL.
    Clinically relevant drug-drug interactions in primary care. Am Fam Physician 2019;99(9):558-64.
    OpenUrl
  37. 37.↵
    1. Patel D,
    2. Bertz R,
    3. Ren S,
    4. Boulton DW,
    5. Någård M.
    A systematic review of gastric acid-reducing agent-mediated drug-drug interactions with orally administered medications. Clin Pharmacokinet 2020;59(4):447-62.
    OpenUrl
  38. 38.↵
    1. Skelin M,
    2. Lucijanić T,
    3. Amidžić Klarić D,
    4. Rešić A,
    5. Bakula M,
    6. Liberati-Čizmek AM, et al.
    Factors affecting gastrointestinal absorption of levothyroxine: a review. Clin Ther 2017;39(2):378-403. Epub 2017 Jan 30.
    OpenUrl
  39. 39.
    1. Pitman SK,
    2. Hoang UTP,
    3. Wi CH,
    4. Alsheikh M,
    5. Hiner DA,
    6. Percival KM.
    Revisiting oral fluoroquinolone and multivalent cation drug-drug interactions: are they still relevant? Antibiotics (Basel) 2019;8(3):108.
    OpenUrl
  40. 40.
    1. Ogawa R,
    2. Echizen H.
    Clinically significant drug interactions with antacids: an update. Drugs 2011;71(14):1839-64.
    OpenUrlPubMed
  41. 41.
    1. Neuvonen PJ.
    Interactions with the absorption of tetracyclines. Drugs 1976;11(1):45-54.
    OpenUrlCrossRefPubMed
  42. 42.
    Tetracyclines (CPhA monograph). Ottawa, ON: Canadian Pharmacists Association; 2018. Available from: https://www.e-therapeutics.ca/. Accessed 2022 Sep 4.
  43. 43.
    1. Rock AE,
    2. DeMarais PL,
    3. Vergara-Rodriguez PT,
    4. Max BE.
    HIV-1 virologic rebound due to coadministration of divalent cations and bictegravir. Infect Dis Ther 2020;9(3):691-6. Epub 2020 Jul 4.
    OpenUrl
  44. 44.↵
    Liverpool Drug Interactions Group. Integrase inhibitors and cations. Drug interactions between integrase strand transfer inhibitors and cations. Liverpool, UK: University of Liverpool; 2022. Available from: https://liverpool-hiv-hep.s3.amazonaws.com/prescribing_resources/pdfs/000/000/184/original/Cations_2022_Oct.pdf?1668697942. Accessed 2022 Jan 11.
  45. 45.↵
    1. Simonson W.
    Should vitamin C routinely be given with oral iron supplements? Geriatr Nurs 2019;40(3):327-8. Epub 2019 May 16.
    OpenUrl
  46. 46.↵
    1. Khan AA,
    2. Alrob HA,
    3. Ali DS,
    4. Dandurand K,
    5. Wolfman W,
    6. Fortier M.
    Guideline no. 422g: menopause and osteoporosis. J Obstet Gynaecol Can 2022;44(5):527-36.e5.
    OpenUrl
  47. 47.↵
    1. Walden DM,
    2. Khotimchenko M,
    3. Hou H,
    4. Chakravarty K,
    5. Varshney J.
    Effects of magnesium, calcium, and aluminum chelation on fluoroquinolone absorption rate and bioavailability: a computational study. Pharmaceutics 2021;13(5):594.
    OpenUrl
  48. 48.↵
    1. Coulson RL,
    2. LaSalle JM.
    Epigenetics of circadian rhythms in imprinted neurodevelopmental disorders. Prog Mol Biol Transl Sci 2018;157:67-92. Epub 2018 Apr 12.
    OpenUrl
  49. 49.↵
    1. Ballesta A,
    2. Innominato PF,
    3. Dallmann R,
    4. Rand DA,
    5. Lévi FA.
    Systems chronotherapeutics. Pharmacol Rev 2017;69(2):161-99.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Liang L,
    2. Kung JY,
    3. Mitchelmore B,
    4. Cave A,
    5. Banh HL.
    Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: a systematic review and network meta-analysis. J Clin Hypertens (Greenwich) 2022;24(5):536-54. Epub 2022 Mar 2.
    OpenUrl
  51. 51.↵
    1. Hermida RC,
    2. Ayala DE,
    3. Mojón A,
    4. Fernández JR.
    Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens 2008;21(8):948-54. Epub 2008 Jul 3.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Villeco JP.
    Edema: a silent but important factor. J Hand Ther 2012;25(2):153-62. Epub 2011 Dec 31.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Singh SK,
    2. Revand R.
    Physiological basis of lower limb edema. In: Tiwary SK, editor. Approach to lower limb oedema. Gateway East, Singapore: Springer Nature Sinapore Pte Ltd; 2022. p. 25-43.
  54. 54.↵
    1. Van Gastel A.
    Drug-induced insomnia and excessive sleepiness. Sleep Med Clin 2022;17(3):471-84. Epub 2022 Sep 8.
    OpenUrl
  55. 55.↵
    1. Kim D,
    2. Procyshyn R,
    3. Barr A.
    Insomnia. Ottawa, ON: Canadian Pharmacists Association; 2022. Available from: https://www.e-therapeutics.ca/. Accessed 2022 Nov 19.
  56. 56.↵
    1. Grannell L.
    When should I take my medicines? Aust Prescr 2019;42(3):86-9. Epub 2019 Jun 3.
    OpenUrl
  57. 57.↵
    Aricept (donepezil hydrochloride): highlights of prescribing information. Nutley, NJ: Eisai Inc; 2021. Available from: http://www.aricept.com/. Accessed 2023 Jan 10.
  58. 58.↵
    1. Agboton C,
    2. Mahdavian S,
    3. Singh A,
    4. Ghazvini P,
    5. Hill A,
    6. Sweet R.
    Impact of nighttime donepezil administration on sleep in the older adult population: a retrospective study. Ment Health Clin 2014;4(5):257-9.
    OpenUrl
  59. 59.↵
    1. Song HR,
    2. Woo YS,
    3. Wang HR,
    4. Jun TY,
    5. Bahk WM.
    Effect of the timing of acetylcholinesterase inhibitor ingestion on sleep. Int Clin Psychopharmacol 2013;28(6):346-8.
    OpenUrl
  60. 60.↵
    1. Hermida RC,
    2. Ayala DE,
    3. Mojón A,
    4. Fernández JR.
    Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010;27(8):1629-51.
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Hermida RC,
    2. Crespo JJ,
    3. Domínguez-Sardiña M,
    4. Otero A,
    5. Moyá A,
    6. Ríos MT, et al.
    Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2020;41(48):4565-76.
    OpenUrlPubMed
  62. 62.↵
    1. Turgeon RD,
    2. Althouse AD,
    3. Cohen JB,
    4. Enache B,
    5. Hogenesch JB,
    6. Johansen ME, et al.
    Lowering nighttime blood pressure with bedtime dosing of antihypertensive medications: controversies in hypertension—con side of the argument. Hypertension 2021;78(3):871-8. Epub 2021 Aug 11.
    OpenUrlPubMed
  63. 63.↵
    1. Mackenzie IS,
    2. Rogers A,
    3. Poulter NR,
    4. Williams B,
    5. Brown MJ,
    6. Webb DJ, et al.
    Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 2022;400(10361):1417-25. Epub 2022 Oct 11.
    OpenUrlCrossRef
  64. 64.↵
    1. Garrison SR,
    2. Kolber MR,
    3. Allan GM,
    4. Bakal J,
    5. Green L,
    6. Singer A, et al.
    Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial. BMJ Open 2022;12(2):e059711.
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Awad K,
    2. Serban MC,
    3. Penson P,
    4. Mikhailidis DP,
    5. Toth PP,
    6. Jones SR, et al.
    Effects of morning vs evening statin administration on lipid profile: a systematic review and meta-analysis. J Clin Lipidol 2017;11(4):972-85.e9. Epub 2017 Jun 13.
    OpenUrl
  66. 66.↵
    1. Awad K,
    2. Banach M.
    The optimal time of day for statin administration: a review of current evidence. Curr Opin Lipidol 2018;29(4):340-5.
    OpenUrl
PreviousNext
Back to top

In this issue

Canadian Family Physician: 69 (2)
Canadian Family Physician
Vol. 69, Issue 2
1 Feb 2023
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Improper administration
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Improper administration
Jessie Vitic, Erin Yakiwchuk, Alex Crawley
Canadian Family Physician Feb 2023, 69 (2) 107-112; DOI: 10.46747/cfp.6902107

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Improper administration
Jessie Vitic, Erin Yakiwchuk, Alex Crawley
Canadian Family Physician Feb 2023, 69 (2) 107-112; DOI: 10.46747/cfp.6902107
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Case presentation
    • Timing medications with food
    • Important drug-mineral interactions
    • Medications at the optimal time of day
    • Case resolution
    • Conclusion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • Une administration inappropriée
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Une administration inappropriée
  • Mild asthma in adults and adolescents
Show more RxFiles

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2023 by The College of Family Physicians of Canada

Powered by HighWire